**Name of Journal: World Journal of Hepatology**

**ESPS Manuscript NO: 20030**

**Manuscript Type: EDITORIAL**

**Clinical and biological significance of precursor lesions of intrahepatic cholangiocarcinoma**

Ettel M *et al*. Significance of precursor lesions of ICC

Mark Ettel, Ogechukwu Eze, Ruliang Xu

**Mark Ettel, Ogechukwu Eze, Ruliang Xu,** Department of Pathology, NYU School of Medicine, New York, NY 10016, United States

**Author contributions:** All the authors equally contributed to this work.

**Conflict-of-interest statement:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Ruliang Xu, MD, PhD,** Department of Pathology, NYU School of Medicine, 560 First Avenue, New York, NY 10016, United States. ruliang.xu@nyumc.org

**Telephone:** +1-212-2630728

**Fax:** +1-212-2637916

**Received:** May 27, 2015

**Peer-review started:** May 30, 2015

**First decision:** June 18, 2015

**Revised:** July 22, 2015

**Accepted:** October 16, 2015

**Article in press:**

**Published online:**

**Abstract**

Cholangiocarcinoma (CC) is primarily a malignant tumor of older adults most prevalent in Southeast Asia, where liver fluke infestation is high. However the etiology in western countries is unknown. Although the incidence of extrahepatic cholangiocarcinoma has remained constant, incidence of intrahepatic cholangiocarcinoma (ICC) which differs in morphology, pathogenesis, risk factors, treatment and prognosis is increasing. While this increase is associated with hepatitis C virus infection, chronic nonalcoholic liver disease, obesity, and smoking, the pathogenesis of ICC and molecular alterations underlying the carcinogenesis are not completely elucidated. Benign biliary lesions such as biliary intraepithelial neoplasia, intraductal papillary neoplasm of the bile duct, von Meyenburg complex or bile duct hamartoma, and bile duct adenoma have been associated with ICC. For each of these entities, evidence suggests or supports a role as premalignant lesions. This article summarized the important biological significance of the precursor lesions of ICC and the molecular mechanisms that may be involved in intrahepatic cholangiocarcinogenesis.

**Key words:** Intrahepatic cholangiocarcinoma; Intraepithelial neoplasia; Intraductal papillary neoplasm of the bile duct; Von Meyenburg complex or bile duct hamartoma; Bile duct adenoma

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This manuscript highlights the important development in the research field of intrahepatic cholangiocarcinogenesis, and summarizes some key points related to progression from the precursor lesions to the intrahepatic cholangiocarcinoma, including their molecular genetics. Each individual precursor or potential precursor is linked to the cancer by the clinical, histological and molecular association.

Ettel M, Eze O, Xu R. Clinical and biological significance of precursor lesions of intrahepatic cholangiocarcinoma. *World J Hepatol* 2015; In press

**INTRODUCTION**

Intrahepatic cholangiocarcinoma is responsible for 10%-20% of primary liver cancers worldwide[[1](#_ENREF_1)]. Intrahepatic cholangiocarcinomas (ICCs) are classified as perihilar or peripheral type. The perihilar type, involving the large bile ducts, is composed of a large tubular component or papillary proliferation of tall columnar epithelium with mucin production. The peripheral type, involving the smaller ducts and segmental branches, is composed of a proliferation of relatively small, tubular, closely packed cord-like structures or ductular pattern lined by small cuboidal epithelium[[2](#_ENREF_2)]. Grossly, both perihilar and peripheral intrahepatic cholangiocarcinoma are firm and white to tan[[1](#_ENREF_1)]. Another classification scheme divides ICCs into conventional ductal carcinoma, bile ductular type, intraductal neoplasm and rare variants[[3](#_ENREF_3)], highlighting similarities between intraductal neoplasms and pancreatic intraductal papillary-mucinous neoplasms, and differences between bile ductular type and the conventional type on the origin of tumor cells*.* These classification schemes reflect the postulated cells of tumor origin with similaritiesbetween the perihilar type, conventional ductal carcinoma, bile duct type and mucin-producing type, and between the peripheral, bile ductular, cholangiolar and cholangiolocellular types[[2](#_ENREF_2)].

ICCs may evolve from two types of premalignant biliary lesions; biliary intraepithelial neoplasia (BilIN) and intraductal papillary neoplasm of the bile duct (IPNB)[[3](#_ENREF_3)] as in the case of perihilar large duct type ICCs[[4](#_ENREF_4)]. ICC may also evolve without definite premalignant lesions. No intraepithelial or intraductal preneoplastic, dysplastic or neoplastic lesions have been demonstrated in the small bile ducts or ductules[[5](#_ENREF_5)]. Von Meyenburg complex (VMC) is suggested to be a possible premalignant lesion of ICCs due to the occasional association of VMC with ICCs and reports of VMC-like cystic ICCs[[6-8](#_ENREF_6)]. Progression of bile duct adenoma (BDA) to ICC has also been reported[[9](#_ENREF_9)]. The major clinical and histological characteristic features of above lesions are summarized in Table 1 and Figure 1. In addition to these precursor lesions, incidence is also increased in patients with risk factors such as chronic viral hepatitis, infection with parasites such as clonorchis and opistorchis, and hepatolithiasis[[1](#_ENREF_1)].

**BILIARY INTRAEPITHELIAL NEOPLASIA**

Biliary intraepithelial neoplasia (BilIN) is an epithelial lesion and a precursor to both ICCs (the intrahepatic bile ducts and peribiliary gland) and to extrahepatic cholangiocarcinoma (the extrahepatic bile ducts and gallbladder)[[10](#_ENREF_10),[11](#_ENREF_11)]. BilIN is characterized by epithelial cells with nuclear pseudostratification and atypia, often with micropapillary projections into the bile duct lumen[[10](#_ENREF_10)]. It is not grossly identifiable[[10](#_ENREF_10)]. BilIN has often been described as the biliary counterpart to pancreatic intraepithelial neoplasia (PanIN), partially due to the similar embryonal development and morphology of the pancreatic and biliary duct systems[[12](#_ENREF_12)]. Grading of BilIN follows a similar 3-tiered pattern to that of PanIN, which has proven similar in several morphologic and immunohistochemical respects[[13](#_ENREF_13)]. BilIN is subdivided into BilIN-1, BilIN-2 and BilIN-3 according to consensus criteria proposed in 2005 and accepted by an international group in 2007[[14](#_ENREF_14),[15](#_ENREF_15)]. BilIN-1 shows relatively uniform, mildly irregular nuclei confined to the lower two thirds of the epithelium. In BilIN-2, nuclei are full-thickness and can be found apically, and loss of cellular and nuclear polarity is present but not diffuse. Nuclear irregularity is increased compared to BilIN-1, but mitoses remain rare. BilIN-3 is notable for marked cellular and nuclear atypia and loss of polarity, with cytological resemblance to invasive cholangiocarcinoma albeit without basement membrane invasion. Cribriforming and budding of cell clusters as well as mitoses are often seen[[11](#_ENREF_11),[15](#_ENREF_15)]. Macroscopic and radiologic identification of these lesions is not possible[[11](#_ENREF_11)].

BilIN has been associated with several conditions which can predispose to cholangiocarcinoma. There is no solid datum about the prevalence of BilIN. While estimates of overall prevalence of BilIN are difficult to determine, one study for margin status in biliary carcinomas showed that 4 of 19 ICCs had BilIN at the margin[[16](#_ENREF_16)].

BilIN is frequently diagnosed in cases of hepatolithiasis[[17](#_ENREF_17)], and primary sclerosing cholangitis (PSC) and choledochal cyst have also been associated with BilIN[[15](#_ENREF_15),[18](#_ENREF_18)]. BilIN has also been shown to arise in autoimmune pancreatitis, chronic hepatitis B and C, and alcoholic cirrhosis[[19-21](#_ENREF_19)].

BilIN shares several molecular alterations with cholangiocarcinoma, and study of BilIN alongside cholangiocarcinoma has helped to elucidate several of the key molecular mechanisms in cholangiocarcinogenesis. Many of these molecular changes accumulate in conjunction with increasing grade of BilIN[[11](#_ENREF_11)]. KRAS has been shown to occur early in cholangiocarcinogenesis and is present in approximately 33% of BilIN lesions including in 25% of cases of BilIN-1[[22](#_ENREF_22)]. Also, p21, p53, cyclin D1 and EZH2 expression has been shown to increase and expression of Dcp4 and p16INK4A decreases in tandem with increasing grade of BilIN[[3](#_ENREF_3)]. Importantly, p53 overexpression has been shown in BilIN-3 but reports show no increased expression in BilIN-1/2[[17](#_ENREF_17),[22](#_ENREF_22)]. Overexpression of EZH2 has been related to hypermethylation of the p16 promoter, which could explain the correlating increase in EZH2 expression and decrease of p16 expression with increasing grade of BilIN[[23](#_ENREF_23)]. Overexpression in EZH2 and decreased p16 expression are associated with deregulation of cellular senescence, and deregulation of autophagy has been shown through in vitro studies to precede cellular senescence[[24](#_ENREF_24),[25](#_ENREF_25)]. Related to these findings, it is notable that a recent study of expression of autophagy-related proteins showed that light chain 3β (LC3), beclin-1 and p62 showed increased expression in BilIN-1, BilIN-2 and BilIN-3, suggesting that deregulated autophagy plays a role in occurrence and development of BilIN[[17](#_ENREF_17)]. Decreased membranous expression of β-catenin similarly correlates with increasing grade of BilIN, while E-cadherin is decreased in some cases of BilIN but in a smaller proportion of cases compared to invasive cholangiocarcinoma[[26](#_ENREF_26)]. S100P also showed increased immunohistochemical expression in BilIN-2 and BilIN-3 as compared to reactive benign epithelium and BilIN-1[[27](#_ENREF_27)]. The S100P immunohistochemical marker is of particular interest as it has been suggested for use in clinical diagnosis and grading of BilIN[[11](#_ENREF_11)].

**INTRADUCTAL PAPILLARY NEOPLASM OF THE BILE DUCT**

Intraductal papillary neoplasm of the bile duct (IPNB), defined as a precursor to cholangiocarcinoma according to the WHO 2010 classification, has been described as the biliary counterpart to the intraductal papillary mucinous neoplasm (IPMN) of the pancreas[[10](#_ENREF_10),[28](#_ENREF_28)]. Similarly to IPMN, the neoplasm is characterized by thin fibrovascular cores lined with noninvasive papillary or villous epithelium and filling a dilated bile duct lumen[[10](#_ENREF_10)]. Grossly, IPNB shows dilated, fusiform to cystic bile ducts with soft papillary lesions ranging from white to tan to red. Histologically, the aforementioned fibrovascular cores are lined by any of four cell types: pancreatobiliary, intestinal, gastric and oncocytic types, parallel to those defined in IPMN[[10](#_ENREF_10)]. However, there are important differences between IPNB and IPMN. Only approximately 1/3 of IPNB show macroscopic mucin production, while only rare IPMNs are not associated with mucin hypersecretion[[28](#_ENREF_28),[29](#_ENREF_29)]. Also, pancreatobiliary type epithelium is most common and gastric type epithelium is rare in IPNB, whereas IPMN least commonly shows pancreatobiliary differentiation[[10](#_ENREF_10)] and gastric is among the more common patterns[[30](#_ENREF_30)]. Just as grading of BilIN parallels that of PanIN, grading in IPNB follows that of IPMN. Low, intermediate and high grade are assigned based on cytologic and architectural characteristics, where low- and intermediate-grade tumors comprise one diagnostic entity, high-grade tumors another, and IPNB with associated invasive carcinoma a final separate entity[[10](#_ENREF_10)]. Studies of histomorphologic, molecular and other features of these tumors have shown disparate results to some extent due to the different features of IPNB with different etiology.

IPNB comprises 9%-38% of bile duct carcinomas and is most common in patients from far eastern countries in their 6th and 7th decades[[28](#_ENREF_28)]. In these patients who often have risk factors such as hepatolithiasis and clonorchiasis, intestinal subtype is most common (47% and 38% in two large series)[[31](#_ENREF_31),[32](#_ENREF_32)]. However, western cohorts more commonly show pancreatobiliary type epithelium (36%, 69% and 45% of patients in three recent series from the United States and western Europe)[[30](#_ENREF_30),[33](#_ENREF_33),[34](#_ENREF_34)]. Series in all populations have shown uncommon oncocytic and gastric subtypes.

Molecular changes in IPNB remain poorly characterized, although several recent studies have begun to explore various molecular mechanisms in these precursor neoplasms. Comparisons between IPNB and BilIN have shown conflicting results. Cyclin D1 and p21 expression increase occurs in IPNB just as it does in in BilIN; a study by Itatsu *et al*[[26](#_ENREF_26)] showed higher expression in IPNB than in BilIN while Nakanishi *et al*[[35](#_ENREF_35)] did not find this differential expression. Another cell cycle protein, p16, has also shown aberrant expression in IPNB and this aberrant expression was shown to be more frequent in cholangiocarcinoma than in IPNB[[30](#_ENREF_30)]. Inactivation of p53 has been shown to increase with increasing grade of dysplasia and with invasion in one study[[30](#_ENREF_30)], while other studies have shown different results[[35](#_ENREF_35),[36](#_ENREF_36)]. C-myc mutations have been shown to be common as well with expression in over half of cases in one study[[26](#_ENREF_26)]. Similar to pancreatic neoplasms, loss of SMAD4/DPC4 has been shown in IPNB and BilIN with increased loss associated with higher grade[[30](#_ENREF_30),[35](#_ENREF_35)]. GNAS mutation has been seen mostly in intestinal subtype and mucin hypersecretion-associated cases, and has been recognized more frequently in studies involving Asian cohorts where intestinal subtype is more common[[30](#_ENREF_30),[37](#_ENREF_37)]. KRAS mutations on the other hand appear more common in early and low-grade lesions[[28](#_ENREF_28),[30](#_ENREF_30)].

**VON MEYENBURG COMPLEX (BILE DUCT HAMARTOMA)**

Von Meyenburg complexes (VMCs), also known variously as bile duct or biliary hamartomas or as biliary microhamartomas, are small (generally < 5 mm), well-circumscribed unencapsulated nodules which consist of irregularly shaped, often dilated bile ducts lined by a low cuboidal epithelium, embedded within a dense collagenous stroma. VMCs are thought to result from persistence of the embryonic ductal plate and are generally adjacent to portal areas[[1](#_ENREF_1)]. Multiple case reports showed exist of VMCs with histologic evidence of transformation to cholangiocarcinoma, showing benign, hyperplastic and dysplastic epithelium with adjacent progression to invasive carcinoma[[7](#_ENREF_7),[8](#_ENREF_8),[38](#_ENREF_38),[39](#_ENREF_39)].

These lesions are fairly common with prevalence of 5.6% in adults and 0.9% of children in one autopsy series, and are especially prevalent in patients with adult polycystic kidney disease or congenital hepatic fibrosis[[40](#_ENREF_40)]. VMCs are generally considered benign, but several case reports suggest that these lesions are capable of transformation to cholangiocarcinoma, showing benign, hyperplastic and dysplastic epithelium with adjacent progression to invasive carcinoma, particularly in patients with multiple VMCs[[8](#_ENREF_8),[38](#_ENREF_38),[39](#_ENREF_39),[41-43](#_ENREF_41)]. This phenomenon has been corroborated with molecular evidence of mutations shared between cholangiocarcinoma and VMCs[[44](#_ENREF_44)]. Further suggesting this link is a radiologic study of 6 patients with multiple VMCs in which one of the six (17%) patients with initial imaging evidence of VMCs developed cholangiocarcinoma within 2 years[[45](#_ENREF_45)].

Specific molecular genetic changes for transformation of VMCs to cholangiocarcinoma have not been definitively established[[38](#_ENREF_38)]. In contrast to biliary duct adenomas, BRAF V600E mutations seen in a subset of intrahepatic cholangiocarcinoma are not present in VMCs[[46](#_ENREF_46)]. However, recent studies have identified multiple findings suggestive of the sequential genetic changes required for transformation of benign VMCs to invasive cholangiocarcinoma[[38](#_ENREF_38),[44](#_ENREF_44)]. In one study of two patients with multiple VMCs and cholangiocarcinoma, loss of heterozygosity (LOH) was examined at 20 key genetic loci in the cholangiocarcinoma tumor, in VMCs distant from the tumor, and in intermediate lesions where VMCs showed transformation to cholangiocarcinoma. LOH was seen in VMCs at some of the same key loci as seen in cholangiocarcinoma, affecting oncogenes p16, p53, APC and PTEN which have been shown to play a role in the development of cholangiocarcinoma[[44](#_ENREF_44)]. In contrast, immunohistochemical expression of p16INK4A was shown to be lost in cholangiocarcinoma in one report while adjacent uninvolved VMC ducts retained expression of p16INK4A[[38](#_ENREF_38)].

**BILE DUCT ADENOMA OR PERIBILIARY GLAND HAMARTOMA**

Bile duct adenoma (BDA)are small (< 2 cm) benign gray to white, yellow or tan lesions usually located directly beneath the liver capsule. They are firm, well-circumscribed and not encapsulated. Histologically, they are comprised of uniform tubular or curvilinear ductules within a fibrous stroma[[47](#_ENREF_47),[48](#_ENREF_48)]. The ductules are lined by cuboidal cells with bland, round to oval nuclei and without mitotic activity, and sometimes show mucinous metaplasia, 1-antitrypsin droplets and neuroendocrine differentiation. Previously synonymous with bile duct hamartoma (BDH)[[49](#_ENREF_49)] - BDA and BDH have overlapping features - histological findings and immunohistochemical properties aid in distinguishing between the two. It has been reported that BDAs originate from peri-biliary glands and not bile ductules or ducts[[50](#_ENREF_50)]. This finding is supported by the monoclonal antibody identification of antigens D10 and IF6 and the presence of mucin cells; a shared profile amongst peribiliary glands and BDAs but not VMCs. Malignant transformation of BDA has not been unequivocally demonstrated. ICC in a background of BDA mixed with minor component of BDH is reported in the literature[[51](#_ENREF_51)] (also present in authors’ unpublished case report). There has also been a report of progression of BDA to ICC[[9](#_ENREF_9)]. BDA is a rare lesion and has been found in 0.0008%-0.006% of patients in two large autopsy series[[52](#_ENREF_52),[53](#_ENREF_53)].

Molecular characterization of BDAs is incomplete. The BRAF V600E mutation was identified by PCR and immunohistochemistry in 53% (8/15) cases of BDA in one series[[46](#_ENREF_46)]. Interestingly, both wild-type BRAF and BRAF V600E lesions coexisted in patients with multiple BDAs. Identification of oncogenic mutations in BDA supports a benign neoplasm rather than reactive process and suggests that BDA may be an early lesion in the pathogenesis of ICC, which has been shown to harbor BRAF V600E mutations[[54](#_ENREF_54),[55](#_ENREF_55)]. Furthermore, the finding of coexistence of benign lesions, dysplastic lesions and carcinoma (authors’ unpublished data) and progression of BDA to ICC[[9](#_ENREF_9)] strongly suggests an adenoma-dysplasia-carcinoma pathway, as seen in colorectal carcinogenesis. BRAF V600E mutation was not identified in von Meyenberg complexes, supporting distinct etiologies with different molecular and biological processes[[46](#_ENREF_46)].

**BILIARY ADENOFIBROMA**

Few cases of biliary adenofibroma[[56-59](#_ENREF_56)], a benign tumor with complex tubulocystic nonmucin secreting biliary epithelial and an abundant fibroblastic stromal components, have been reported to date. The immunohistochemical profile (cytokeratins 7, 8, 18, 19 and D10 positive, and 1F6 negative) suggests a large bile duct or interlobular duct origin[[59](#_ENREF_59),[60](#_ENREF_60)]. Malignant transformation of the epithelial component has been reported[[56](#_ENREF_56)].

**MOLECULAR GENETICS OF ICCS AND PRECURSORS**

Molecular alterations underlying ICC and the premalignant biliary lesions are not completely elucidated. Activating mutations in KRAS (22%), loss-of-function mutations in TP53 (15%), BRAF and EGFR mutation (7% and 2%), and rare NRAS and PI3K mutations have been reported[[55](#_ENREF_55),[61-72](#_ENREF_61)]. IDH1 and IDH2 mutations co-occurring with increased TP53 expression and associated with DNA hypermethylation has also been reported, although the functional relevance is unknown. Chromosomal aberrations including gains at 7p and 8q and losses at 1p, 4q and 9p were identified by comparative genomic hybridization studies[[69](#_ENREF_69),[73-76](#_ENREF_73)]. Aberrant methylation of p16INK4a/CDKN2 (47%), RASSFIA (56%) and APC (29%) genes have been demonstrated in ICC although the exact role in the pathogenesis is also not delineated. Investigation of genetic and epigenetic alterations in benign intrahepatic biliary lesions will further highlight mechanisms of carcinogenesis.

**REFERENCES**

1 **Goodman Z,** Terracciano L, Wee A. Tumours and tumour-like lesions of the liver. In: Burt A, Portmann B, Ferrell L, editors. MacSween's Pathology of the Liver. 6th ed. Edinburgh: Elsevier, 2012

2 **Aishima S**, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. *J Hepatobiliary Pancreat Sci* 2015; **22**: 94-100 [PMID: 25181580 DOI: 10.1002/jhbp.154]

3 **Nakanuma Y**, Sasaki M, Sato Y, Ren X, Ikeda H, Harada K. Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. *World J Hepatol* 2009; **1**: 35-42 [PMID: 21160963 DOI: 10.4254/wjh.v1.i1.35]

4 **Nakanuma Y**, Tsutsui A, Ren XS, Harada K, Sato Y, Sasaki M. What are the precursor and early lesions of peripheral intrahepatic cholangiocarcinoma? *Int J Hepatol* 2014; **2014**: 805973 [PMID: 24860673 DOI: 10.1155/2014/805973]

5 **Aishima S**, Nishihara Y, Tsujita E, Taguchi K, Soejima Y, Taketomi A, Ikeda Y, Maehara Y, Tsuneyoshi M. Biliary neoplasia with extensive intraductal spread associated with liver cirrhosis: a hitherto unreported variant of biliary intraepithelial neoplasia. *Hum Pathol* 2008; **39**: 939-947 [PMID: 18430455 DOI: 10.1016/j.humpath.2007.10.031]

6 **Blanc JF**, Bernard PH, Carles J, Le Bail B, Balabaud C, Bioulac-Sage P. Cholangiocarcinoma arising in Von Meyenburg complex associated with hepatocellular carcinoma in genetic haemochromatosis. *Eur J Gastroenterol Hepatol* 2000; **12**: 233-237 [PMID: 10741940 DOI: 10.1097/00042737-200012020-00016]

7 **Jain D**, Sarode VR, Abdul-Karim FW, Homer R, Robert ME. Evidence for the neoplastic transformation of Von-Meyenburg complexes. *Am J Surg Pathol* 2000; **24**: 1131-1139 [PMID: 10935654 DOI: 10.1097/00000478-200008000-00011]

8 **Song JS**, Lee YJ, Kim KW, Huh J, Jang SJ, Yu E. Cholangiocarcinoma arising in von Meyenburg complexes: report of four cases. *Pathol Int* 2008; **58**: 503-512 [PMID: 18705771 DOI: 10.1111/j.1440-1827.2008.02264.x]

9 **Pinho AC**, Melo RB, Oliveira M, Almeida M, Lopes J, Graça L, Costa-Maia J. Adenoma-carcinoma sequence in intrahepatic cholangiocarcinoma. *Int J Surg Case Rep* 2012; **3**: 131-133 [PMID: 22326450 DOI: 10.1016/j.ijscr.2012.01.002]

10 **Bosman F,** Carneiro F, Hruban R, Theise N. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press, 2010

11 **Sato Y**, Sasaki M, Harada K, Aishima S, Fukusato T, Ojima H, Kanai Y, Kage M, Nakanuma Y, Tsubouchi H. Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia. *J Gastroenterol* 2014; **49**: 64-72 [PMID: 23616173 DOI: 10.1007/s00535-013-0810-5]

12 **Nakanuma Y**, Harada K, Sasaki M, Sato Y. Proposal of a new disease concept "biliary diseases with pancreatic counterparts". Anatomical and pathological bases. *Histol Histopathol* 2014; **29**: 1-10 [PMID: 24108502]

13 **Sato Y**, Harada K, Sasaki M, Nakanuma Y. Histological Characterization of Biliary Intraepithelial Neoplasia with respect to Pancreatic Intraepithelial Neoplasia. *Int J Hepatol* 2014; **2014**: 678260 [PMID: 24860672 DOI: 10.1155/2014/678260]

14 **Zen Y**, Aishima S, Ajioka Y, Haratake J, Kage M, Kondo F, Nimura Y, Sakamoto M, Sasaki M, Shimamatsu K, Wakasa K, Park YN, Chen MF, Atomi Y, Nakanuma Y. Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement. *Pathol Int* 2005; **55**: 180-188 [PMID: 15826244 DOI: 10.1111/j.1440-1827.2005.01816.x]

15 **Zen Y**, Adsay NV, Bardadin K, Colombari R, Ferrell L, Haga H, Hong SM, Hytiroglou P, Klöppel G, Lauwers GY, van Leeuwen DJ, Notohara K, Oshima K, Quaglia A, Sasaki M, Sessa F, Suriawinata A, Tsui W, Atomi Y, Nakanuma Y. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. *Mod Pathol* 2007; **20**: 701-709 [PMID: 17431410 DOI: 10.1038/modpathol.3800788]

16 **Matthaei H**, Lingohr P, Strässer A, Dietrich D, Rostamzadeh B, Glees S, Roering M, Möhring P, Scheerbaum M, Stoffels B, Kalff JC, Schäfer N, Kristiansen G. Biliary intraepithelial neoplasia (BilIN) is frequently found in surgical margins of biliary tract cancer resection specimens but has no clinical implications. *Virchows Arch* 2015; **466**: 133-141 [PMID: 25425476 DOI: 10.1007/s00428-014-1689-0]

17 **Sasaki M**, Nitta T, Sato Y, Nakanuma Y. Autophagy may occur at an early stage of cholangiocarcinogenesis via biliary intraepithelial neoplasia. *Hum Pathol* 2015; **46**: 202-209 [PMID: 25466963 DOI: 10.1016/j.humpath.2014.09.016]

18 **Katabi N**, Pillarisetty VG, DeMatteo R, Klimstra DS. Choledochal cysts: a clinicopathologic study of 36 cases with emphasis on the morphologic and the immunohistochemical features of premalignant and malignant alterations. *Hum Pathol* 2014; **45**: 2107-2114 [PMID: 25123074 DOI: 10.1016/j.humpath.2014.06.016]

19 **Ohtani H**, Ishida H, Ito Y, Yamaguchi T, Koizumi M. Autoimmune pancreatitis and biliary intraepithelial neoplasia of the common bile duct: a case with diagnostically challenging but pathogenetically significant association. *Pathol Int* 2011; **61**: 481-485 [PMID: 21790863 DOI: 10.1111/j.1440-1827.2011.02684.x]

20 **Aishima S,** Iguchi T, Fujita N, Taketomi A, Maehara Y, Tsuneyoshi M, Oda Y. Histological and immunohistological findings in biliary intraepithelial neoplasia arising from a background of chronic biliary disease compared with liver cirrhosis of non-biliary aetiology. *Histopathology* 2011; **59**: 867-875 [PMID: 22092398 DOI: 10.1111/j.1365-2559.2011.04011.x]

21 **Wu TT**, Levy M, Correa AM, Rosen CB, Abraham SC. Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases. *Cancer* 2009; **115**: 4564-4575 [PMID: 19670455 DOI: 10.1002/cncr.24471]

22 **Hsu M**, Sasaki M, Igarashi S, Sato Y, Nakanuma Y. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. *Cancer* 2013; **119**: 1669-1674 [PMID: 23335286 DOI: 10.1002/cncr.27955]

23 **Sasaki M**, Yamaguchi J, Itatsu K, Ikeda H, Nakanuma Y. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. *J Pathol* 2008; **215**: 175-183 [PMID: 18393368 DOI: 10.1002/path.2345]

24 **Young AR**, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot JF, Tavaré S, Arakawa S, Shimizu S, Watt FM, Narita M. Autophagy mediates the mitotic senescence transition. *Genes Dev* 2009; **23**: 798-803 [PMID: 19279323 DOI: 10.1101/gad.519709]

25 **Sasaki M**, Miyakoshi M, Sato Y, Nakanuma Y. Autophagy mediates the process of cellular senescence characterizing bile duct damages in primary biliary cirrhosis. *Lab Invest* 2010; **90**: 835-843 [PMID: 20212459 DOI: 10.1038/labinvest.2010.56]

26 **Itatsu K**, Zen Y, Ohira S, Ishikawa A, Sato Y, Harada K, Ikeda H, Sasaki M, Nimura Y, Nakanuma Y. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. *Liver Int* 2007; **27**: 1174-1184 [PMID: 17919228 DOI: 10.1111/j.1478-3231.2007.01577.x]

27 **Aishima S**, Fujita N, Mano Y, Kubo Y, Tanaka Y, Taketomi A, Shirabe K, Maehara Y, Oda Y. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. *Am J Surg Pathol* 2011; **35**: 590-598 [PMID: 21412073 DOI: 10.1097/pas.0b013e31820ffdf1]

28 **Ohtsuka M**, Shimizu H, Kato A, Yoshitomi H, Furukawa K, Tsuyuguchi T, Sakai Y, Yokosuka O, Miyazaki M. Intraductal papillary neoplasms of the bile duct. *Int J Hepatol* 2014; **2014**: 459091 [PMID: 24949206 DOI: 10.1155/2014/459091]

29 **Ohtsuka M**, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Suda K, Takano S, Kondo Y, Miyazaki M. Similarities and differences between intraductal papillary tumors of the bile duct with and without macroscopically visible mucin secretion. *Am J Surg Pathol* 2011; **35**: 512-521 [PMID: 21412069 DOI: 10.1097/pas.0b013e3182103f36]

30 **Schlitter AM**, Born D, Bettstetter M, Specht K, Kim-Fuchs C, Riener MO, Jeliazkova P, Sipos B, Siveke JT, Terris B, Zen Y, Schuster T, Höfler H, Perren A, Klöppel G, Esposito I. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. *Mod Pathol* 2014; **27**: 73-86 [PMID: 23828315 DOI: 10.1038/modpathol.2013.112]

31 **Kim KM**, Lee JK, Shin JU, Lee KH, Lee KT, Sung JY, Jang KT, Heo JS, Choi SH, Choi DW, Lim JH. Clinicopathologic features of intraductal papillary neoplasm of the bile duct according to histologic subtype. *Am J Gastroenterol* 2012; **107**: 118-125 [PMID: 21946282 DOI: 10.1038/ajg.2011.316]

32 **Ji Y**, Fan J, Zhou J, Wang BS, Liu HB, Wu ZW, Tan YS. Intraductal papillary neoplasms of bile duct. A distinct entity like its counterpart in pancreas. *Histol Histopathol* 2008; **23**: 41-50 [PMID: 17952856]

33 **Kloek JJ**, van der Gaag NA, Erdogan D, Rauws EA, Busch OR, Gouma DJ, ten Kate FJ, van Gulik TM. A comparative study of intraductal papillary neoplasia of the biliary tract and pancreas. *Hum Pathol* 2011; **42**: 824-832 [PMID: 21292296 DOI: 10.1016/j.humpath.2010.09.017]

34 **Rocha FG**, Lee H, Katabi N, DeMatteo RP, Fong Y, D'Angelica MI, Allen PJ, Klimstra DS, Jarnagin WR. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? *Hepatology* 2012; **56**: 1352-1360 [PMID: 22504729 DOI: 10.1002/hep.25786]

35 **Nakanishi Y**, Zen Y, Kondo S, Itoh T, Itatsu K, Nakanuma Y. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. *Hum Pathol* 2008; **39**: 1153-1161 [PMID: 18495210 DOI: 10.1016/j.humpath.2007.11.018]

36 **Abraham SC**, Lee JH, Hruban RH, Argani P, Furth EE, Wu TT. Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. *Hum Pathol* 2003; **34**: 902-910 [PMID: 14562286 DOI: 10.1016/s0046-8177(03)00337-x]

37 **Sasaki M**, Matsubara T, Yoneda N, Nomoto K, Tsuneyama K, Sato Y, Nakanuma Y. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct. *Histopathology* 2013; **62**: 446-457 [PMID: 23163606 DOI: 10.1111/his.12016]

38 **Parekh V,** Peker D. Malignant Transformation in Von-Meyenburg Complexes: Histologic and Immunohistochemical Clues With Illustrative Cases. *Appl Immunohistochem Mol Morphol* 2015 Mar 16; Epub ahead of print [PMID: 25789533 DOI: 10.1097/pai.0000000000000132]

39 **Xu AM**, Xian ZH, Zhang SH, Chen XF. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature. *Eur J Gastroenterol Hepatol* 2009; **21**: 580-584 [PMID: 19282767 DOI: 10.1097/meg.0b013e3282fc73b1]

40 **Redston MS**, Wanless IR. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected]. *Mod Pathol* 1996; **9**: 233-237 [PMID: 8685220]

41 **Neto AG**, Dainiak C, Qin L, Salem RR, Jain D. Intraductal papillary cholangiocarcinoma associated with von Meyenberg complexes: a case report. *Dig Dis Sci* 2007; **52**: 2643-2645 [PMID: 17394067 DOI: 10.1007/s10620-007-9777-5]

42 **Orii T**, Ohkohchi N, Sasaki K, Satomi S, Watanabe M, Moriya T. Cholangiocarcinoma arising from preexisting biliary hamartoma of liver--report of a case. *Hepatogastroenterology* 2003; **50**: 333-336 [PMID: 12749215]

43 **Röcken C**, Pross M, Brucks U, Ridwelski K, Roessner A. Cholangiocarcinoma occurring in a liver with multiple bile duct hamartomas (von Meyenburg complexes). *Arch Pathol Lab Med* 2000; **124**: 1704-1706 [PMID: 11079031 DOI: 10.1043/0003-9985(2000)124<1704: coialw>2.0.co; 2]

44 **Jain D**, Ahrens W, Finkelstein S. Molecular evidence for the neoplastic potential of hepatic Von-Meyenburg complexes. *Appl Immunohistochem Mol Morphol* 2010; **18**: 166-171 [PMID: 19770706 DOI: 10.1097/pai.0b013e3181b94fd8]

45 **Luo TY**, Itai Y, Eguchi N, Kurosaki Y, Onaya H, Ahmadi Y, Niitsu M, Tsunoda HS. Von Meyenburg complexes of the liver: imaging findings. *J Comput Assist Tomogr* 1998; **22**: 372-378 [PMID: 9606376 DOI: 10.1097/00004728-199805000-00006]

46 **Pujals A**, Bioulac-Sage P, Castain C, Charpy C, Zafrani ES, Calderaro J. BRAF V600E mutational status in bile duct adenomas and hamartomas. *Histopathology* 2015; **67**: 562-567 [PMID: 25704541 DOI: 10.1111/his.12674]

47 **Ferrell L.** Benign and Malignant Tumors of the Liver. In: Odze R, Goldblum J, editors. Odze and Goldblum Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. 3rd ed. Philadelphia: Elsevier, 2014

48 **Allaire GS**, Rabin L, Ishak KG, Sesterhenn IA. Bile duct adenoma. A study of 152 cases. *Am J Surg Pathol* 1988; **12**: 708-715 [PMID: 3046396 DOI: 10.1097/00000478-198809000-00007]

49 **Börnfors M**. The development of cholangiocarcinoma from multiple bile-duct adenomas. Report of a case and review of the literature. *Acta Pathol Microbiol Immunol Scand A* 1984; **92**: 285-289 [PMID: 6093427 DOI: 10.1111/j.1699-0463.1984.tb04405.x]

50 **Bhathal PS**, Hughes NR, Goodman ZD. The so-called bile duct adenoma is a peribiliary gland hamartoma. *Am J Surg Pathol* 1996; **20**: 858-864 [PMID: 8669534 DOI: 10.1097/00000478-199607000-00009]

51 **Hasebe T**, Sakamoto M, Mukai K, Kawano N, Konishi M, Ryu M, Fukamachi S, Hirohashi S. Cholangiocarcinoma arising in bile duct adenoma with focal area of bile duct hamartoma. *Virchows Arch* 1995; **426**: 209-213 [PMID: 7757293 DOI: 10.1007/bf00192644]

52 **Edmonson HA.** Tumors of the liver and intrahepatic bile ducts. Washington, DC: Armed Forces Institute of Pathology, 1958: 18-24, 179-190

53 **Cho C**, Rullis I, Rogers LS. Bile duct adenomas as liver nodules. *Arch Surg* 1978; **113**: 272-274 [PMID: 205188]

54 **Goeppert B**, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, Warth A, Vogel MN, Mehrabi A, Hafezi M, Boehmer K, von Deimling A, Schirmacher P, Weichert W, Capper D. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. *Mod Pathol* 2014; **27**: 1028-1034 [PMID: 24309328 DOI: 10.1038/modpathol.2013.206]

55 **Tannapfel A**, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. *Gut* 2003; **52**: 706-712 [PMID: 12692057 DOI: 10.1136/gut.52.5.706]

56 **Akin O**, Coskun M. Biliary adenofibroma with malignant transformation and pulmonary metastases: CT findings. *AJR Am J Roentgenol* 2002; **179**: 280-281 [PMID: 12076957 DOI: 10.2214/ajr.179.1.1790280]

57 **Parada LA**, Bardi G, Hallén M, Hägerstrand I, Tranberg KG, Mitelman F, Johansson B. Monosomy 22 in a case of biliary adenofibroma. *Cancer Genet Cytogenet* 1997; **93**: 183-184 [PMID: 9078308 DOI: 10.1016/s0165-4608(96)00224-5]

58 **Tsui WM**, Loo KT, Chow LT, Tse CC. Biliary adenofibroma. A heretofore unrecognized benign biliary tumor of the liver. *Am J Surg Pathol* 1993; **17**: 186-192 [PMID: 8422113 DOI: 10.1097/00000478-199302000-00010]

59 **Varnholt H**, Vauthey JN, Dal Cin P, Marsh Rde W, Bhathal PS, Hughes NR, Lauwers GY. Biliary adenofibroma: a rare neoplasm of bile duct origin with an indolent behavior. *Am J Surg Pathol* 2003; **27**: 693-698 [PMID: 12717255 DOI: 10.1097/00000478-200305000-00014]

60 **Gurrera A**, Alaggio R, Leone G, Aprile G, Magro G. Biliary adenofibroma of the liver: report of a case and review of the literature. *Patholog Res Int* 2010; **2010**: 504584 [PMID: 21151526 DOI: 10.4061/2010/504584]

61 **Andersen JB**, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. *Gastroenterology* 2012; **142**: 1021-1031.e15 [PMID: 22178589 DOI: 10.1053/j.gastro.2011.12.005]

62 **Borger DR**, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. *Oncologist* 2012; **17**: 72-79 [PMID: 22180306 DOI: 10.1634/theoncologist.2011-0386]

63 **Chen TC**, Jan YY, Yeh TS. K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy. *Ann Surg Oncol* 2012; **19** Suppl 3: S675-S681 [PMID: 22805857 DOI: 10.1245/s10434-012-2224-7]

64 **Deshpande V**, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. *BMC Cancer* 2011; **11**: 60 [PMID: 21303542 DOI: 10.1186/1471-2407-11-60]

65 **Furubo S**, Harada K, Shimonishi T, Katayanagi K, Tsui W, Nakanuma Y. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. *Histopathology* 1999; **35**: 230-240 [PMID: 10469215 DOI: 10.1046/j.1365-2559.1999.00705.x]

66 **Kipp BR**, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores GJ, Halling KC. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. *Hum Pathol* 2012; **43**: 1552-1558 [PMID: 22503487 DOI: 10.1016/j.humpath.2011.12.007]

67 **Leone F**, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. *Clin Cancer Res* 2006; **12**: 1680-1685 [PMID: 16551849 DOI: 10.1158/1078-0432.ccr-05-1692]

68 **Momoi H**, Itoh T, Nozaki Y, Arima Y, Okabe H, Satoh S, Toda Y, Sakai E, Nakagawara K, Flemming P, Yamamoto M, Shimahara Y, Yamaoka Y, Fukumoto M. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. *J Hepatol* 2001; **35**: 235-244 [PMID: 11580146 DOI: 10.1016/s0168-8278(01)00106-4]

69 **Sia D**, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology* 2013; **144**: 829-840 [PMID: 23295441 DOI: 10.1053/j.gastro.2013.01.001]

70 **Tannapfel A**, Benicke M, Katalinic A, Uhlmann D, Köckerling F, Hauss J, Wittekind C. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. *Gut* 2000; **47**: 721-727 [PMID: 11034592 DOI: 10.1136/gut.47.5.721]

71 **Tannapfel A**, Sommerer F, Benicke M, Weinans L, Katalinic A, Geissler F, Uhlmann D, Hauss J, Wittekind C. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. *J Pathol* 2002; **197**: 624-631 [PMID: 12210082 DOI: 10.1002/path.1139]

72 **Tannapfel A**, Weinans L, Geissler F, Schütz A, Katalinic A, Köckerling F, Hauss J, Wittekind C. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. *Dig Dis Sci* 2000; **45**: 317-324 [PMID: 10711445]

73 **Homayounfar K**, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. *Hum Pathol* 2009; **40**: 834-842 [PMID: 19200581 DOI: 10.1016/j.humpath.2008.11.005]


74 **Koo SH**, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Cancer Genet Cytogenet* 2001; **130**: 22-28 [PMID: 11672769 DOI: 10.1016/s0165-4608(01)00460-5]

75 **Uhm KO**, Park YN, Lee JY, Yoon DS, Park SH. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. *Cancer Genet Cytogenet* 2005; **157**: 37-41 [PMID: 15676145 DOI: 10.1016/j.cancergencyto.2004.05.007]

76 **Wong N**, Li L, Tsang K, Lai PB, To KF, Johnson PJ. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. *J Hepatol* 2002; **37**: 633-639 [PMID: 12399230 DOI: 10.1016/s0168-8278(02)00269-6]

**P-Reviewer:** Shi ZJ, Yagi H **S-Editor:** Tian YL

**L-Editor: E-Editor:**

****

**Figure 1 Premalignant biliary lesions.** A: Biliary intraepithelial neoplasia. Biliary epithelium with nuclear pseudostratification and atypia; B: Intraductal papillary neoplasm of the bile duct. Papillary proliferation of neoplastic cells lining thin fibrovascular cores; C: Von Meyenburg complex. Small well-circumscribed lesion consisting of dilated irregular bile ducts embedded within dense collagenous stroma; D: Bile duct adenoma. Well-circumscribed proliferation of small uniform tubules surrounded by fibrous stroma.

**Table 1 Summary of the clinical and pathological features of intrahepatic cholangiocarcinoma and its precursor lesions**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **ICC** | **BilIN** | **IPNB** | **VMC/BDH** | **BDA** |
| Incidence/prevalence | 10%-20% of primary liver cancers[[1](#_ENREF_1)] | No published data | 9%-38% of bile duct carcinomas[[28](#_ENREF_28)] | 5.6% of adults, 0.9% of children (autopsy series)[[40](#_ENREF_40)] | 0.00008%-0.006% of patients (autopsy series)[[52](#_ENREF_52), [53](#_ENREF_53)] |
| Risk factors | Chronic viral hepatitis, Clonorchis, Opistorchis, hepatolithiasis[[1](#_ENREF_1)] | Hepatolithiasis, primary sclerosing cholangitis, choledochal cyst, autoimmune pancreatitis, chronic viral hepatitis, alcoholic cirrhosis[[15](#_ENREF_15),1[7](#_ENREF_18)-21] | Hepatolithiasis, clonorchis[[31](#_ENREF_31),[32](#_ENREF_32)] | Congenital hepatic fibrosis, polycystic liver disease[[40](#_ENREF_40)] | No known risk factors |
| Gross appearance | Firm, white to tan[[1](#_ENREF_1)] | Not grossly identifiable[[10](#_ENREF_10)] | Dilated bile ducts filled with soft, papillary white to red to tan lesions without invasion[[10](#_ENREF_10)] | Well-circumscribed unencapsulated nodules, < 5 mm[[1](#_ENREF_1)] | Subcapsular, well-circumscribed unencapsulated gray to white, yellow or tan firm nodules, ≤ 2 cm[[47](#_ENREF_47),[48](#_ENREF_48)] |
| Histologic appearance | Perihilar type: involves large bile ducts, composed of large tubules or papillae lined by columnar epithelium  Peripheral type: involves smaller ducts and segmental branches, composed of small, tubular cords or ductular pattern lined by cuboidal epithelium[[2](#_ENREF_1)] | Epithelium with nuclear pseudostratification and atypia (increasing from BilIN-1 to BilIN-2 to BilIN-3), often with micropapillary projections into the bile duct lumen[[10](#_ENREF_10)] | Noninvasive papillary or villous biliary neoplasm covering delicate fibrovascular stalks (subtypes pancreatobiliary, intestinal, gastric, oncocytic) [[10](#_ENREF_10)] | Irregular dilated to branching low cuboidal epithelium-lined ductules within fibrous stroma, often adjacent to portal areas[[1](#_ENREF_1)] | Small uniform cuboidal epithelium-lined ductules within fibrous stroma[[47](#_ENREF_47), [48](#_ENREF_48)] |
| Molecular alterations | Activating mutations in KRAS (22%) occurs early in cholangiocarcinogenesis[63]  Loss-of-function mutations in TP53 (15%), BRAF and EGFR mutation (7% and 2%)[55,61,65,67]  Rare NRAS and PI3K mutations have been [55,61-72]  IDH1 and IDH2 mutations co-occurring with increased TP53 expression and associated with DNA hypermethylation[62,66]  Chromosomal aberrations including gains at 7p and 8q and losses at 1p, 4q and 9p[68-69,[73-76](#_ENREF_69)]  Aberrant methylation of p16INK4a/CDKN2 (47%), RASSFIA (56%) and APC (29%)[70-71,76] | Activating mutation of KRAS present in approximately 33% of BilIN lesions including in 25% of cases of BilIN-1[22]  Increased expression of p21, p53, cyclin D1 and EZH2[[3](#_ENREF_2),17,22-25]  Decreased expression of Dcp4 and p16INK4A. Loss of SMAD4/DPC4 associated with higher grade[[3](#_ENREF_28),[30,](#_ENREF_33)35]  Decreased membranous expression of β-catenin with increasing grade of BilIN [26]  Decreased expression of E-cadherin in some cases of BilIN[[2](#_ENREF_2)6]  S100P: increased immunohistochemical expression in BilIN-2 and BilIN-3[2[7](#_ENREF_25)] | Increased expression of Cyclin D1 and p21[[26](#_ENREF_26),[35](#_ENREF_35)]  Aberrant expression of p16[[30](#_ENREF_28)]  Inactivation of p53 associated with increasing grade of dysplasia and invasion[[30](#_ENREF_28)]  C-myc mutations in over 50% of cases[[2](#_ENREF_24)6]  Loss of SMAD4/DPC4 associated with higher grade[30,3[5](#_ENREF_33)] | Loss of heterozygosity at key loci (5q21, 9p21, 10q23, 17p13)harboring APC, p53, p16, and PTEN [44] | BRAF V600E mutation (53%)[[4](#_ENREF_45)6] |

BilIN: Biliary intraepithelial neoplasia; IPNB: Intraductal papillary neoplasm of the bile duct; VMC: Von Meyenburg complex; BDH: Bile duct hamartoma; BDA: Bile duct adenoma; ICC: Intrahepatic cholangiocarcinoma.